Conclusion

Abstract

In the last few decades, nanotechnology has entered every phase of consumer products, especially in the design of medicines for the diagnosis and treatment of terminating illness like cancer. Undoubtedly, extensive research in nanobiomedicine will definitely produce safe, highly efficient, and highly sensitive medicines for oral and intravenous administrations and for early-stage cancer detection and monitoring schemes. These systems are already improving key issues like specific targeting, increase therapeutic efficacies, reduce side effects, and overcome drug resistance to certain extent.